WASHINGTON, April 9, 2026
Vanda Pharmaceuticals Inc. has publicly called on the U.S. Food and Drug Administration (FDA) to withdraw a proposed legislative change included in its FY 2027 Congressional Budget Justification, warning that the proposal could significantly extend drug approval timelines and reduce regulatory transparency. The company argues that the changes would delay patient access to innovative therapies, increase uncertainty for drug developers, and undermine long-standing statutory protections designed to ensure timely review of new drug applications (NDAs).
Proposed Changes Could Extend Drug Approval Timelines
At the center of the debate is the FDA’s proposal to eliminate the statutory requirement mandating a 180-day review period for NDAs, replacing it with longer performance goals under the Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee Amendments (GDUFA). Under the current system, the FDA may take up to two months to determine whether to file an application, after which the official review period begins, resulting in total review times of approximately 10 to 12 months.
Vanda argues that formalizing this approach would institutionalize delays rather than improve efficiency, contradicting the broader goal of accelerating access to life-saving therapies. The company emphasized that such changes could have a significant impact on patients awaiting new treatments, particularly those with serious or unmet medical needs, where timely access to therapies is critical.
Concerns Over Transparency and Regulatory Oversight
Advertisement
In addition to timeline changes, the proposal includes replacing the formal evidentiary hearing process for drug non-approvals with a streamlined internal appeals mechanism. Vanda has raised concerns that this shift could reduce transparency and limit due process, making it more difficult for companies to challenge regulatory decisions.
The company highlighted its own recent legal experience, where a U.S. Court of Appeals ruling determined that the FDA had failed to provide a legally required hearing in a drug approval case, marking the first such hearing granted in over 40 years. According to Vanda, the proposed changes could weaken accountability within the regulatory system, potentially affecting both innovation and patient trust in the drug approval process.
Impact on Biopharma Innovation and Patient Access
From an industry perspective, the proposed regulatory changes could have far-reaching implications for biopharmaceutical innovation, particularly for small and mid-sized companies that rely on predictable regulatory timelines to manage development costs and investment risks. Extended review periods may lead to higher financial burdens, delayed commercialization, and reduced incentives for innovation, especially in areas with high unmet medical need.
Vanda emphasized that while efforts to streamline regulatory processes and reduce inefficiencies are important, the current proposal may achieve the opposite by entrenching longer timelines and increasing bureaucratic complexity. The company has urged both the FDA and Congress to prioritize policies that enhance efficiency, transparency, and timely access to therapies, rather than introducing measures that could slow down the drug development lifecycle.
From a cGxP and regulatory compliance standpoint, maintaining clear, predictable, and enforceable review timelines is essential for ensuring efficient drug development, regulatory accountability, and patient safety. Any changes to these frameworks must carefully balance innovation, regulatory rigor, and patient access, ensuring that the system continues to support both scientific advancement and public health objectives.
The call by Vanda Pharmaceuticals to withdraw the FDA’s proposed legislative changes highlights a critical debate within the biopharmaceutical and regulatory landscape, focusing on the balance between efficiency, transparency, and innovation. As policymakers evaluate the proposal, the outcome will have significant implications for drug approval timelines, industry dynamics, and patient access to new therapies. Ensuring that regulatory frameworks support both rapid innovation and robust oversight will be essential in shaping the future of global pharmaceutical development and healthcare delivery.
Source: Vanda Pharmaceuticals press release
